Aequus Pharmaceuticals Inc (AEQ.SG)
| Previous close | 0.0000 |
| Open | 0.0000 |
| Bid | 0.0470 x N/A |
| Ask | 0.0598 x N/A |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 28 May 2024 - 03 June 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Aequus Pharmaceuticals Full Year 2023 Earnings: CA$0.022 loss per share (vs CA$0.024 loss in FY 2022)
Aequus Pharmaceuticals ( CVE:AQS ) Full Year 2023 Results Key Financial Results Revenue: CA$254.9k (down 82% from FY...
GlobeNewswireAequus Reports Second Quarter 2023 Financial Highlights and General Update
VANCOUVER, British Columbia, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing, and promoting differentiated products, today reports financial results for the quarter ended June 30, 2023 (“Second Quarter 2023”) and associated Company developments. Unless otherwise noted, all figures are in Canadian currency. Doug Janzen shares that “we are very optimistic w
- GlobeNewswire
Aequus Announces Zimed PF Now Available in Canada
VANCOUVER, British Columbia, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), ) (“Aequus” or the “Company”), a specialty pharmaceutical company announced today, we are thrilled to announce the launch of Zimed® PF, the first preservative-free multi-dose Bimatoprost for glaucoma patients in Canada. "This marks a new growth phase for Aequus and the launch of a Preservative Free (PF) innovation that brings value to both physicians and patients in a large ther
